行情

PTLA

PTLA

Portola Pharma
NASDAQ

实时行情|Nasdaq Last Sale

27.21
+0.34
+1.27%
盘后: 27.21 0 0.00% 16:44 11/15 EST
开盘
27.13
昨收
26.87
最高
27.77
最低
26.77
成交量
68.28万
成交额
--
52周最高
37.95
52周最低
14.81
市值
21.17亿
市盈率(TTM)
-6.5595
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTLA 新闻

  • Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians
  • PR Newswire.1天前
  • Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
  • Zacks.11/08 16:31
  • Cantor likes CV Sciences in premarket analyst action
  • Seeking Alpha - Article.11/08 12:47
  • Goldman Sachs Initiates Coverage On Portola Pharmaceuticals with Neutral Rating
  • Benzinga.11/08 11:36

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

PTLA 简况

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
展开

Webull提供Portola Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。